Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$34.14
-HK$0.03(-0.33%)
At close: 4:00 PM EST
HK$34.14
-HK$0.03(-0.33%)
Day’s Range― - ―
52-Week RangeHK$15.32 - HK$35.34
Previous CloseN/A
Volume4.35M
Average Volume (3M)5.91M
Market Cap
HK$23.96B
Enterprise ValueHK$21.20B
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Sep 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.27Price Target Upside15.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.13B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA ~61% revenue increase in 2025 indicates accelerating commercial adoption of its surgical robotics. Durable top-line growth improves the prospect of scaling fixed-cost investments, enabling operating leverage and stronger unit economics if the company sustains market penetration over the next 2–6 months and beyond.
Positive Gross MarginA positive ~29% gross margin shows the core product economics are viable at the unit level. That margin provides a foundation for eventual operating profitability as revenue scales and R&D/SG&A leverage improves, supporting longer-term margin sustainability if commercial momentum continues.
Improving LeverageA materially lower debt-to-equity ratio reduces financial risk and interest burden, increasing runway and flexibility for commercial investment. Improved leverage positions the company to fund continued product rollouts with less insolvency risk, aiding durability of operations and strategy execution.
Bears Say
Persistent UnprofitabilityA deep net loss (≈-45% margin) shows the business has not yet reached sustainable profitability. Continued negative margins erode equity, limit internal capital for growth, and require recurring external funding, making long-term independence and stable returns uncertain absent clear path to operating breakeven.
Negative Cash GenerationRepeated negative operating and free cash flow means the company cannot self-fund expansion and must rely on financing. That increases dilution or debt risk, constrains the pace of clinical/commercial rollout, and creates execution risk if capital markets tighten or fundraising becomes costly.
Very Weak Returns & Eroding EquityA roughly -59% ROE and falling equity indicate persistent operational losses are eroding shareholder capital. Such structural poor returns weaken investor confidence, complicate future capital raises, and signal the company must materially improve profitability to restore sustainable capital formation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$15.32 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$23.96B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 71 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.161 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.161.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is -0.01.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.161 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$39.27 (15.02% Upside)
HK$39.27 (15.02% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
-52.78%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$39.27
▲(15.02% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---